Pharmacokinetics of colistin methanesulfonate (CMS) in burn patients

J Antimicrob Chemother. 2017 Jan;72(1):319-321. doi: 10.1093/jac/dkw361. Epub 2016 Sep 2.

Authors

Silvia Corcione¹, Lorena Baietto², Valeria Malvasio³, Maurizio Stella³, Giovanni Di Perri², Antonio D'Avolio², Francesco Giuseppe De Rosa²

Affiliations

¹ Department of Medical Sciences, University of Turin, Infectious Diseases at Amedeo di Savoia Hospital, Turin, Italy corcione.silvia@gmail.com.
² Department of Medical Sciences, University of Turin, Infectious Diseases at Amedeo di Savoia Hospital, Turin, Italy.
³ Department of Plastic Surgery, Burns Unit, CTO Hospital, Turin, Italy.

PMID: 27591295
DOI: 10.1093/jac/dkw361

No abstract available

Publication types

Letter

MeSH terms

Acinetobacter Infections / drug therapy*
Acinetobacter Infections / microbiology
Acinetobacter Infections / prevention & control*
Acinetobacter baumannii / drug effects*
Acinetobacter baumannii / isolation & purification
Aged
Anti-Bacterial Agents / pharmacokinetics*
Anti-Bacterial Agents / therapeutic use*
Area Under Curve
Burns / therapy*
Colistin / analogs & derivatives*
Colistin / pharmacokinetics
Colistin / therapeutic use
Female
Humans
Male
Middle Aged

Substances

Anti-Bacterial Agents
colistinmethanesulfonic acid
Colistin